SG10201509063SA - Substituted benzamides and their uses - Google Patents

Substituted benzamides and their uses

Info

Publication number
SG10201509063SA
SG10201509063SA SG10201509063SA SG10201509063SA SG10201509063SA SG 10201509063S A SG10201509063S A SG 10201509063SA SG 10201509063S A SG10201509063S A SG 10201509063SA SG 10201509063S A SG10201509063S A SG 10201509063SA SG 10201509063S A SG10201509063S A SG 10201509063SA
Authority
SG
Singapore
Prior art keywords
substituted benzamides
benzamides
substituted
Prior art date
Application number
SG10201509063SA
Other languages
English (en)
Inventor
Denise Chan
Michael Patrick Hay
Muriel Bonnet
Connie Sun
Ray Tabibiazar
Po-Wai Yuen
Amato Giaccia
Olga Razorenova
Edwin Lai
Original Assignee
Univ Leland Stanford Junior
Auckland Uniservices Ltd
Ruga Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior, Auckland Uniservices Ltd, Ruga Corp filed Critical Univ Leland Stanford Junior
Publication of SG10201509063SA publication Critical patent/SG10201509063SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/62Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG10201509063SA 2012-04-12 2013-04-11 Substituted benzamides and their uses SG10201509063SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261623517P 2012-04-12 2012-04-12
US201361791823P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
SG10201509063SA true SG10201509063SA (en) 2015-12-30

Family

ID=49328285

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201406518XA SG11201406518XA (en) 2012-04-12 2013-04-11 Substituted benzamides and their uses
SG10201509063SA SG10201509063SA (en) 2012-04-12 2013-04-11 Substituted benzamides and their uses

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201406518XA SG11201406518XA (en) 2012-04-12 2013-04-11 Substituted benzamides and their uses

Country Status (13)

Country Link
US (1) US9296732B2 (fr)
EP (1) EP2838534A4 (fr)
JP (1) JP2015516393A (fr)
KR (1) KR20150013475A (fr)
CN (1) CN104411311A (fr)
AU (1) AU2013245809A1 (fr)
CA (1) CA2873701A1 (fr)
HK (1) HK1207301A1 (fr)
IL (1) IL235145A0 (fr)
MX (1) MX2014012294A (fr)
RU (1) RU2014141510A (fr)
SG (2) SG11201406518XA (fr)
WO (1) WO2013155338A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2627324A4 (fr) * 2010-10-11 2014-05-07 Univ Leland Stanford Junior Benzamides substitués et leurs utilisations
WO2015078799A1 (fr) * 2013-11-27 2015-06-04 Bayer Pharma Aktiengesellschaft Inhibiteurs de transport de glucose
WO2016028971A1 (fr) 2014-08-21 2016-02-25 Bristol-Myers Squibb Company Dérivés rattachés de benzamide utilisés comme puissants inhibiteurs de rock
WO2016202935A1 (fr) 2015-06-19 2016-12-22 Bayer Pharma Aktiengesellschaft Inhibiteurs de transport du glucose
WO2020113094A1 (fr) 2018-11-30 2020-06-04 Nuvation Bio Inc. Composés pyrrole et pyrazole et leurs procédés d'utilisation
CA3166630A1 (fr) 2020-01-03 2021-07-08 Berg Llc Amides polycycliques utilises en tant que modulateurs d'ube2k pour le traitement du cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
TW200404789A (en) 1999-03-15 2004-04-01 Axys Pharm Inc Novel compounds and compositions as protease inhibitors
US6835731B2 (en) * 2000-09-15 2004-12-28 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
EP1369420A1 (fr) 2002-06-06 2003-12-10 Aventis Pharma Deutschland GmbH Inhibiteurs d'interaction GPib-vWF
US7235558B2 (en) 2002-06-06 2007-06-26 Sanofi-Aventis Deutschland Gmbh Inhibitors of the GPIb—vWF interaction, their preparation and use
TW200505446A (en) 2003-01-17 2005-02-16 Fuj Isawa Pharmaceutical Co Ltd Inhibitor of cox
US20080293711A1 (en) 2007-03-08 2008-11-27 Clark Michael P Chemokine receptor modulators
WO2009097113A2 (fr) * 2008-01-28 2009-08-06 New York University Composés oxazole et thiazole utilisés comme modulateurs de la b-caténine et leurs utilisations
US20110105436A1 (en) 2008-03-10 2011-05-05 Auckland Uniservices Limited Heteroaryl compounds, compositions, and methods of use in cancer treatment
HRP20170357T1 (hr) 2008-10-10 2017-05-05 Vm Discovery, Inc. Sastavi i postupci za liječenje poremećaja zbog konzumacije alkohola, bolova i ostalih bolesti
WO2010078408A1 (fr) 2008-12-30 2010-07-08 Biogen Idec Ma Inc. Composés hétéroaryles utiles en tant qu'inhibiteurs de kinase raf
WO2011011514A1 (fr) * 2009-07-21 2011-01-27 The Board Of Trustees Of The Leland Stanford Junior University Hétéroaryl benzamides, compositions et procédés d'utilisation
EP2627324A4 (fr) 2010-10-11 2014-05-07 Univ Leland Stanford Junior Benzamides substitués et leurs utilisations
WO2012100223A1 (fr) 2011-01-21 2012-07-26 John Irwin Ciblage léthal synthétique de transport de glucose

Also Published As

Publication number Publication date
HK1207301A1 (en) 2016-01-29
SG11201406518XA (en) 2014-11-27
MX2014012294A (es) 2015-06-05
CA2873701A1 (fr) 2013-10-17
WO2013155338A3 (fr) 2013-12-27
JP2015516393A (ja) 2015-06-11
WO2013155338A8 (fr) 2015-01-08
EP2838534A4 (fr) 2015-11-11
AU2013245809A1 (en) 2014-11-06
KR20150013475A (ko) 2015-02-05
WO2013155338A2 (fr) 2013-10-17
EP2838534A2 (fr) 2015-02-25
RU2014141510A (ru) 2016-06-10
US9296732B2 (en) 2016-03-29
US20150072976A1 (en) 2015-03-12
IL235145A0 (en) 2014-12-31
CN104411311A (zh) 2015-03-11

Similar Documents

Publication Publication Date Title
IL235826A0 (en) Diazaspirocycloalkane and azaspirocycloalkane
IL234628A0 (en) Imidazolyl-pyrimidines are converted into amino-indolyl and their use as drugs
IL236616A0 (en) 5-aminotetrahydroquinoline-2-new carboxylic acids and their use
IL237309A0 (en) Benzocyclooctyne compounds and uses thereof
IL237926A0 (en) Combinations and their uses
AP2015008406A0 (en) Benzamides
ZA201302854B (en) Substituted benzamides and their uses
ZA201405392B (en) Substituted phenylimidazopyrazoles and use thereof
IL235145A0 (en) Converted benzamides and their use
SG11201504482VA (en) Beta-hexosyl-transferases and uses thereof
PL2882708T3 (pl) Nowe związki i ich zastosowania
GB201301571D0 (en) Product and use
PL2830587T3 (pl) Kompozycja o balansującym i ochronnym wpływie na skórę
GB201222541D0 (en) Kiddibidet and pottibidet
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202021D0 (en) Co-sleeper and breastfeeder
GB201214749D0 (en) Compounds and their uses
GB201213726D0 (en) Novel compounds and their use
GB201215414D0 (en) Composition and use
GB201222342D0 (en) Compounds and uses thereof
GB201206973D0 (en) New compounds and uses
GB201207075D0 (en) New compounds and uses
GB201206055D0 (en) New compounds and uses
AP2015008228A0 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
GB201220504D0 (en) Product and use thereof